D. Boral Capital Reaffirms “Buy” Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $17.00 price target on the stock.

A number of other research firms have also recently issued reports on IMUX. HC Wainwright began coverage on shares of Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price target on shares of Immunic in a research report on Monday, September 9th. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $12.67.

Immunic Stock Performance

Shares of Immunic stock opened at $1.09 on Tuesday. The company’s 50 day moving average price is $1.14 and its 200-day moving average price is $1.32. Immunic has a 52-week low of $0.97 and a 52-week high of $2.11. The stock has a market capitalization of $98.19 million, a price-to-earnings ratio of -0.89 and a beta of 1.88.

Insider Transactions at Immunic

In related news, Director Richard Alan Rudick purchased 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the acquisition, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. State Street Corp raised its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the period. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter worth $50,000. Jane Street Group LLC raised its holdings in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.